Kala launches Eysuvis for the treatment of short-term dry eye

January 08, 2021

1 minute read


We have not been able to process your request. Please try again later. If you continue to experience this problem, please contact [email protected]

Eysuvis is now available for the short-term treatment of dry eye, according to a press release from Kala Pharmaceuticals.

Eysuvis uses Kala’s proprietary Ampplify mucus-penetrating particulate drug delivery technology for enhanced penetration of loteprednol etabonate into target ocular surface tissue to treat the signs and symptoms of dry eye disease. The treatment also offers a favorable tolerance and safety profile and has the potential to complement existing therapies, according to the release.

“We are delighted to announce our second product launch in 2 years, with Eysuvis now available in the United States as the first approved prescription treatment specifically indicated for the short-term treatment of dry eye,” Marc Iwicki, chairman, chairman and chief executive officer of Kala, said in the statement.

The FDA approved Eysuvis in October 2020.



Source link

Comments are closed.